Physician profile
Mark P Scott
NPI 1295717015
$6,461.90
in general payments reported to CMS, 2019-2025
38 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $581 · 2021: $1,341 · 2022: $767 · 2023: $733 · 2024: $957 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $963.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $925.62 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $655.29 | 2019-2024 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $561.97 | 2019-2025 | Nucala, Trelegy Ellipta |
| Electromed, INC. | $430.17 | 2019-2024 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $382.13 | 2019-2024 | Opsumit |
| Grifols USA, LLC | $331.46 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $297.31 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $169.32 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $167.90 | 2019-2020 | |
| Ethicon INC. | $136.68 | 2021 | |
| Zoll Respicardia, INC. | $131.22 | 2021 | |
| Philips North America LLC | $122.70 | 2019-2025 | Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $105.57 | 2019-2022 | |
| Mylan Specialty L.P. | $94.27 | 2019-2023 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $85.85 | 2021-2025 | Arikayce |
| Allergan, INC. | $85.59 | 2019-2020 | |
| Genentech USA, INC. | $69.79 | 2019-2024 | Xolair |
| Olympus America INC. | $67.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $67.82 | 2019-2021 | |
| Harmony Biosciences LLC | $64.68 | 2021-2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $63.54 | 2019-2022 | |
| Amgen INC. | $58.65 | 2024 | Tezspire |
| United Therapeutics Corporation | $50.46 | 2020-2023 | Tyvaso |
| Pulmonx Corporation | $47.61 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Vifor Pharma, INC. | $46.18 | 2024 | Zemaira |
| Circassia INC. | $45.94 | 2019 | |
| Gilead Sciences, INC. | $39.63 | 2021 | |
| Chiesi USA, INC. | $36.40 | 2021 | |
| Baxter Healthcare | $22.12 | 2023 | Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Enterprises LLC | $21.78 | 2019 | |
| Inogen, INC. | $21.47 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Viatris Specialty LLC | $17.92 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.03 | 2021 | |
| Lilly USA, LLC | $16.00 | 2025 | Zepbound |
| Fisher & Paykel Healthcare INC | $15.97 | 2020 | |
| Abbvie INC. | $13.63 | 2023 | Avycaz |
| Pfizer INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.